BPG is committed to discovery and dissemination of knowledge
Featured Articles
3/10/2017 8:42:00 AM | Browse: 894 | Download: 1575
Publication Name World Journal of Gastrointestinal Oncology
Manuscript ID 30551
Country Norway
ISSN 1948-5204 (online)
Open Access This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright © The Author(s) 2017. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website http://www.wjgnet.com
Category Oncology
Manuscript Type Editorial
Article Title Can molecular biomarkers replace a clinical risk score for resectable colorectal liver metastasis?
Manuscript Source Invited Manuscript
All Author List Torhild Veen and Kjetil Søreide
Funding Agency and Grant Number
Corresponding Author Kjetil Søreide, MD, PhD, Professor, Consultant Surgeon, Department of Gastrointestinal Surgery, HPB Unit, Stavanger University Hospital, P.O. Box 8100, N-4068 Stavanger, Norway. ksoreide@mac.com
Key Words Colorectal cancer; Liver metastasis; KRAS; Disease-free survival; Circulating tumor cell; Liver surgery; Overall survival; Molecular biomarkers
Core Tip As a general rule, “good” colorectal liver metastasis (CRLM) cases amenable for surgery have fewer bad genetic traits, such as less likelihood for BRAF mutations or KRAS mutations. KRAS mutation in patients with resectable CRLM suggests a more aggressive disease with shorter progression free and overall survival. Emerging evidence suggest that tumors change during the course of treatment and, thus giving way to new clones that may be of a different genetic makeup and have a different resistance pattern. Thus, new ways of monitoring disease and markers of progression is needed, including circulating cancer biomarkers and tissue-based genetic profiles.
Publish Date 2017-03-09 16:18
Citation Veen T, Søreide K. Can molecular biomarkers replace a clinical risk score for resectable colorectal liver metastasis? World J Gastrointest Oncol 2017; 9(3): 98-104
URL http://www.wjgnet.com/1948-5204/full/v9/i3/98.htm
DOI http://dx.doi.org/10.4251/wjgo.v9.i3.98
Full Article (PDF) WJGO-9-98.pdf
Full Article (Word) WJGO-9-98.doc